Emerging Trends to Drive Pneumococcal Vaccine Market Growth at 6.1% CAGR Through 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Pneumococcal Vaccine Market Size Growth Forecast: What to Expect by 2025?
The market size for the pneumococcal vaccine has seen robust expansion in the past few years. It's projected to rise from $8.94 billion in 2024 to $9.4 billion in 2025, yielding a compound annual growth rate (CAGR) of 5.2%. The growth experienced in the historic period is thanks to factors such as the discovery of streptococcus pneumoniae, public health interest, earlier vaccination initiatives, advancements in healthcare, and modifications in vaccine policy.

How Will the Pneumococcal Vaccine Market Size Evolve and Grow by 2029?
In the coming years, significant expansion is projected for the pneumococcal vaccine market, with an anticipated growth to $11.9 billion in 2029 at a compound annual growth rate of 6.1%. This growth during the forecast period can be tied to the evolution of pneumococcal strains, ongoing research and development, focus on immunization, wider access to vaccines, and an aging population. The key trends expected during this period include the development of multivalent vaccines, vaccination of high-risk groups, improving the efficacy of vaccines, increasing education and awareness campaigns, and focusing on infant immunization.

View the full report here:
https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

What Drivers Are Propelling the Growth of Pneumococcal Vaccine Market Forward?
The rise in cases of pneumococcal contamination is anticipated to fuel the expansion of the pneumococcal vaccine market in the future. Infections caused by a bacterium known as Streptococcus pneumoniae, or pneumococcus, ranging from pneumonia and bloodstream infections to ear and sinus infections, are referred to as pneumococcal contamination. The pneumococcal vaccine works by prompting the body to create antibodies that can counteract pneumococcal bacteria, lessening or eliminating bacteria and toxins that cause diseases. This protects various groups including children, elderly individuals, and those with compromised immune systems from numerous pneumococcal infections. For example, in January 2022, the US public health agency, the Center for Disease Control and Prevention, reported that pneumococcal pneumonia leads to roughly 150,000 hospitalizations annually in the United States, representing up to 30% of all adult community-acquired pneumonia. Therefore, the escalating cases of pneumococcal contamination are contributing to the growth of the pneumococcal vaccine market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11950&type=smp

What Are the Key Trends Driving Pneumococcal Vaccine Market Growth?
Leading firms in the pneumococcal vaccine market are introducing new products to enhance their market profitability. For example, Merck & Co Inc., a pharmaceutical company based in the US, unveiled the V116 vaccine in July 2023. V116 is designed to tackle the eight unique serotypes of Streptococcus pneumoniae that are the main culprits behind adult pneumococcal disease. Compared to other vaccines of its kind, V116 has demonstrated superior immunogenicity for multiple serotypes in adults and incited a robust immune response in individuals, whether they have been vaccinated before or not. V116 is currently in Phase 3 development and has been given "breakthrough therapy" status by the U.S. Food and Drug Administration (FDA).

What Are the Key Segments in the Pneumococcal Vaccine Market?
The pneumococcal vaccine market covered in this report is segmented -

1) By Product Type: Prevnar 13, Synflorix, Pneumovax23, Other Products
2) By Route of Administration: Intravenous, Intramuscular, Subcutaneous
3) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Distribution Channels
4) By End User: Pediatrics, Adults

Subsegments:
1) By Prevnar 13: Pediatric Formulation, Adult Formulation
2) By Synflorix: Pediatric Formulation, Adult Formulation
3) By Pneumovax23: Single-Dose Vials, Pre-Filled Syringes
4) By Other Products: PCV15 (Vaxneuvance), PCV20 (Prevnar 20), Other Regional Pneumococcal Vaccines

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=11950&type=smp

Who Are the Key Players Shaping the Pneumococcal Vaccine Market's Competitive Landscape?
Major companies operating in the pneumococcal vaccine market include Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, Astellas Pharma Inc., CSL Limited, Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Serum Institute of India Private Limited, Emergent BioSolutions Inc., Walvax Biotechnology Co. Ltd, Biological E Limited, Hualan Biological Engineering Inc., Beijing Minhai Biotechnology Limited Company, NPO Petrovax Pharm LLC, Vaxcyte Inc., Panacea Biotec Ltd, Inventprise LLC, Tergene Biotech Private Limited, PnuVax Incorporated, SK Bioscience Co Ltd

What Geographic Markets Are Powering Growth in the Pneumococcal Vaccine Market?
North America was the largest region in the pneumococcal vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumococcal vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11950

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.